检测尿核基质蛋白22筛查膀胱移行细胞癌的临床研究

Clinical study of nuclear matrix protein in urine for detection of bladder cancer

目的探讨检测尿核基质蛋白22（NMP22）在膀胱癌筛查中的应用价值。方法对96例怀疑膀胱癌者进行尿NMP22与尿细胞学检查，比较两者诊断膀胱癌的敏感度和特异度。结果96例患者中病理证实膀胱移行细胞癌55例。非膀胱癌41例。尿NMP22的敏感度为80．0％、特异度为87．8％；尿细胞学检查的敏感度为41．8％、特异度为97．6％。NMP22在膀胱癌筛查中的敏感度优于尿细胞学检查（P〈0．05）。结论尿NMP22检测在膀胱癌筛查中优于尿细胞学检查，可以作为膀胱癌的临床筛查手段。

Objective To evaluate the clinical efficacy of nuclear matrix protein （NMP） as a marker for detection of bladder cancer. Methods For 96 patients suspected with bladder cancer NMP and cytology were determined in the same voided urine samples. The sensitivity and specificity of NMP and urine cytology were analyzed. Results Fifty-five patients were pathologically diagnosed as transitional cell carcinoma, and 41 cases were other urological conditions. The sensitivity and specificity of NMP were 80.0 % and 87.8 % respectively, those of urene cytology were 41.8% and 97.6 % respectively. The sensitivity of NMP was significantly better than urinary cytology in detection of bladder cancer（P 〈 0.05）. Conclusion The NMP test is superior to voided urine cytology in detection of bladder cancer, and it is a effective method for detection of bladder cancer.